Integra Lifesciences Holdings (IART) Net Cash Flow (2009 - 2026)

Integra Lifesciences Holdings' Net Cash Flow history runs 18 years deep, the most recent figure standing at $3.3 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 127.56% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at -$14.3 million (up 95.98% YoY), while the FY2025 annual figure was -$29.3 million, down 24.53% from the prior year.
• Net Cash Flow came in at $3.3 million for Q1 2026 at Integra Lifesciences Holdings, up from $1.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $320.5 million in Q1 2024 to a low of -$375.5 million in Q2 2024.
• A 5-year average of -$16.5 million and a median of -$5.4 million in 2023 frame the typical range for Net Cash Flow.
• On a YoY basis, Net Cash Flow climbed as much as 832.74% in 2024 and fell as far as 18527.13% in 2024.
• Integra Lifesciences Holdings' Net Cash Flow stood at -$67.2 million in 2022, then soared by 92.01% to -$5.4 million in 2023, then soared by 832.74% to $39.3 million in 2024, then plunged by 96.82% to $1.3 million in 2025, then surged by 159.95% to $3.3 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $3.3 million, $1.3 million, and $15.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison